We first confirmed that CNS-homing cells were indeed enriched in the peripheral blood by natalizumab by observing increased cellular expression of the natalizumab target ITGA4 (CD49d) in the circulation of RRMS patients (Figure S3A). Here, ITGA4 is linked to relapsing-remitting multiple sclerosis.